

Press release from Emotra AB (publ)
Göteborg, 17 January, 2022

Disclosure notice and new number of shares following registration of shares subscribed through the TO2 rights issue and the non-cash share issue

Today, on the 17th of January, 2022, Emotra AB (“Emotra” or “the Company”) is proud to announce that the shares issued through exercise of warrants in the TO2 series as well as the Non-Cash Share Issue carried out in connection with the acquisition of NeuraMetrix Inc. (“NeuraMetrix”), which was disclosed on 26 November, 2021 (“the Non-Cash Share Issue”), have been registered by the Swedish Companies Registration Office. Exercise of the TO2-series warrants increased the number of shares by 14,450,356. The Non-Cash Share Issue increased the number of shares in Emotra by 276,241,035. The allotment of newly emitted shares through the Non-Cash Share Issue means that one shareholder has passed the 20 per cent disclosure threshold, one shareholder has passed the 15 per cent disclosure threshold, and four shareholders have passed the 5 per cent disclosure threshold.

Number of shares and share capital

Following the exercise of the warrants in the TO2 series, the number of shares in Emotra grew by 14,450,356 shares, from 82,513,556 to 96,963,912. The Company's share capital also increased by 274,556.76 SEK, from 1,567,757.566 SEK to 1,842,314.33 SEK. The Non-Cash Share Issue increased the number of shares in Emotra by a further 276,241,035 shares, from 96,963,912 to 373,204,947. The Company's share capital thereby increased a further 5,248,579.665 SEK, from 1,842,314.33 SEK to 7,090,893.995 SEK.

Disclosure

In connection with the share dilution caused by the exercise of TO2-series warrants and the Non-Cash Share Issue, Maida Vale Capital AB has passed the disclosure threshold of 20 percent. The number of shares owned by Maida Vale Capital AB is unchanged and still amounts to 21,514,695 shares, but their voting power has decreased to 5.76 per cent, compared to 26.07 per cent of the votes before these transactions.

In connection with the Non-Cash Share Issue, ScanInvest Ltd was allotted an amount of shares in Emotra that pushed them over the 15 per cent disclosure threshold. ScanInvest Ltd now owns 74,387,816 shares and 19.93 per cent of the votes, compared to 0 shares and 0.00 per cent of the votes before the transaction.



In connection with the Non-Cash Share Issue, Jan Samzelius, the Christian Olsson and Pamela Evans Trust, Christina Karlström, and the Wisialowski Living Trust were allotted shares in Emotra. The number of shares they each were allotted exceeds the 5 per cent disclosure threshold. Jan Samzelius owns 35,047,287 shares and 9.39 per cent of the votes, the Christian Olsson and Pamela Evans Trust owns 29,702,810 shares and 7.96 per cent of the votes, Christina Karlström owns 28,610,698 shares and 7.67 per cent of the votes, and the Wisialowski Living Trust owns 18,336,515 shares and 4.91 per cent of the votes. Each of these shareholders owned 0 shares and likewise had no voting power (0.00 per cent) before the transaction.

For further information about Emotra, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93,

E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company's methods/products, NeuraMetrix TC and EDOR®, are unique, proprietary and patent-protected.

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden
Tel: +46 732-34 41 93, www.emotra.se